OPINION — Congress may soon pass a major bill that’s based on a lie
GUEST COLUMN, David Kappos, Council for Innovation Promotion
Just before Christmas, Congress added – and then abruptly dropped – a section of a proposed spending bill aimed at limiting the number of patents pharmaceutical manufacturers could assert in patent litigation.
If lawmakers revisit this bill, Americans suffering from diseases will bear the weight of the consequences.
The lawmakers behind the bill have good intentions. They're trying to prevent exploitation of the patent system in ways that prevent cost-effective drugs from reaching the market.


